ERBB2 and neoplasm: Indeed, we observed an increased proportion of tumours with the HER2-low status among recurrences: 50.0% versus 44.9% at diagnosis, while only 33.8% of tumours were HER2-negative (compared to 39.3% which were HER2-negative at diagnosis).